Results 121 to 130 of about 321,693 (137)

Subcutaneous depo-medroxyprogesterone acetate (DMPA-SC) use in obese and morbidly obese women: incidence of ovulation and follicular development

2015
Background: Subcutaneous depo-medroxyprogesterone acetate (DMPA-SC) has not been studied in the morbidly obese population. The purpose of this 26-week prospective experimental study is to determine incidence of ovulation and follicular development among obese and morbidly obese women after DMPA-SC.
openaire   +1 more source

DMPA-IM, DMPA-SC: Side Effect Differences Few

Pediatric News, 2010
openaire   +1 more source

Investigational DMPA-SC Treats Endometriosis Pain, Curbs BMD Loss

Ob.Gyn. News, 2005
openaire   +1 more source

Few Side Effect Differences Between DMPA-IM, DMPA-SC

Family Practice News, 2010
openaire   +1 more source

Depo Medroxyprogesterone (DMPA) Promotes Papillomavirus Infections but Does Not Accelerate Disease Progression in the Anogenital Tract of a Mouse Model

Viruses, 2022
Vonn Walter, Jiafen Hu, Nancy Cladel
exaly  

DMPA SC dataset

2019
openaire   +1 more source

The effect of DMPA units on ionic conductivity of PEG–DMPA–IPDI waterborne polyurethane as single-ion electrolytes

Polymer, 1999
Chien-Hsin Yang
exaly  

Increased 1-year continuation of DMPA among women randomized to self-administration: results from a randomized controlled trial at Planned Parenthood

Contraception, 2018
Elizabeth J Talmont, Carolyn Westhoff, Julia E Köhn   +2 more
exaly  

Effects of DMPA on weight and blood pressure in long term acceptors

Contraception, 1999
Unnop Jaisamrarn, Surasak Taneepanichskul, Damrong Reinprayoon   +2 more
exaly  

Depot-medroxyprogesterone acetate (DMPA) and cancer of the endometrium and ovary

Contraception, 1994
Pisake Lumbiganon
exaly